Immunome INC 8-K filings

Immunome announced its second quarter 2026 financial results, highlighting the FDA's acceptance of the New Drug Application for varegacestat with a PDUFA target action date of April 28, 2027, and providing updates on its clinical pipeline.

Immunome, Inc. reports the successful election of directors and ratification of auditors at its 2026 Annual Meeting.

Immunome announced positive Phase 3 RINGSIDE trial results for varegacestat in desmoid tumors, alongside full-year 2025 financials and an extended cash runway into 2028.

Immunome, Inc. announced the pricing of its underwritten public offering of 18.625 million common shares at $21.50 each, aiming to raise approximately $400 million in gross proceeds.

Immunome, Inc. announced positive topline results from its Phase 3 RINGSIDE trial for varegacestat in desmoid tumors, showing significant improvement in progression-free survival and objective response rates, with an NDA submission planned for Q2 2026.

Immunome, Inc. announced its third quarter 2025 financial results and provided updates on its advancing oncology pipeline, including positive clinical activity for IM-1021.

Immunome reports second quarter 2025 financial results, highlighting significant progress in clinical programs and a strong cash position.

Immunome, Inc. announced the successful election of two Class II Directors and the overwhelming ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Immunome, Inc. announced its Q1 2025 financial results, highlighting progress in its clinical programs and a strong cash position.

Immunome announces its full year 2024 financial results, highlighting progress in its clinical pipeline and a cash runway extending into 2027.

Immunome, Inc. has announced an underwritten public offering of 19,354,839 shares of its common stock at a price of $7.75 per share, expected to close on January 31, 2025.

Immunome, Inc. announces an underwritten public offering of its common stock and provides an update on its clinical and preclinical oncology pipeline.

Immunome, Inc. offers its CFO, Max Rosett, a relocation package including a $100,000 relocation bonus and a $300,000 housing bonus to incentivize his move to the Bothell, Washington area.

Immunome reported its third quarter 2024 financial results, highlighting progress in its clinical pipeline and a cash runway extending into 2026.

Immunome has acquired Zentalis's antibody-drug conjugate (ADC) platform technology, ROR1 antibodies, and related intellectual property in exchange for stock and a future milestone payment.

Immunome Inc.'s Compensation Committee has approved a new inducement plan, reserving 2 million shares for equity awards to new employees.

Immunome reported its second quarter 2024 financial results, highlighting progress in its clinical pipeline and business development activities.

Immunome Inc. held its 2024 Annual Meeting of Stockholders on June 12, 2024, where stockholders elected two Class I Directors and ratified the selection of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024.

Immunome announced its first quarter 2024 financial results, highlighted by the completion of key integrations and progress in clinical trial preparations.

Immunome Inc. has announced the resignation of its VP of Finance, Corporate Controller, and principal accounting officer, and the appointment of a new principal accounting officer.

Immunome Inc. has appointed Sandra Swain, M.D. to its Board of Directors and Audit Committee, effective April 25, 2024.

Immunome announced its full-year 2023 financial results, highlighted by a transformative year including a merger, pipeline advancements, and a recent acquisition of a Phase 3 asset, with cash runway expected into 2026.

Immunome, Inc. has completed the acquisition of Ayala Pharmaceuticals' AL101 and AL102 programs, including the Phase 3 asset AL102 for desmoid tumors, for an upfront payment of $20 million in cash, 2,175,489 shares of Immunome stock, and potential future milestone payments.

Immunome, Inc. has entered into an underwriting agreement for a public offering of 10 million shares of its common stock at $20.00 per share, aiming to raise $200 million in gross proceeds.

Immunome, Inc. has announced the commencement of an underwritten public offering of its common stock and provided a preliminary estimate of its cash, cash equivalents, and marketable securities balance as of December 31, 2023.

Immunome is set to acquire Ayala Pharmaceuticals' AL102, a Phase 3 asset for desmoid tumors, along with AL101, for an upfront payment of $20 million in cash and $30 million in stock, plus potential milestone payments.

Immunome Inc. has promoted Max Rosett to Executive Vice President, Operations and Interim Chief Financial Officer, and granted him stock options.

Immunome Inc. is advancing three lead oncology programs with IND filings expected in Q1 2025, alongside strategic expansions of its pipeline and technology.